A clinical update on an ALS therapeutic's ongoing trial, covering interim data, biomarker analyses, and upcoming scientific presentations.
Key Takeaways
- Phase 1b study completed enrollment with 41 participants across five dose levels
- Plasma concentrations at the two highest doses reached the preclinical therapeutic exposure range
- Treatment showed an exposure-related decrease in phosphorylated MAP2K4 in PBMCs